Top Page
Sanuwave Health
(NASDAQ:SNWV)
Sanuwave Health (SNWV) vs. SPDR S&P 500 ETF (SPY)
Sanuwave Health Business Overview & Revenue Model
Sanuwave Health Earnings Call Summary
Sanuwave Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.19M | 32.63M | 20.40M | 16.74M | 13.01M | 4.06M |
| Gross Profit | 30.45M | 24.55M | 14.36M | 12.41M | 8.02M | 2.90M |
| EBITDA | -22.01M | -16.56M | -9.15M | 4.79M | -18.90M | -27.38M |
| Net Income | -38.03M | -31.37M | -25.81M | -10.29M | -27.26M | -30.94M |
Balance Sheet | ||||||
| Total Assets | 33.05M | 30.12M | 22.42M | 19.87M | 18.62M | 23.03M |
| Cash, Cash Equivalents and Short-Term Investments | 8.50M | 10.24M | 1.80M | 1.15M | 619.00K | 2.44M |
| Total Debt | 1.18M | 25.50M | 31.94M | 41.11M | 26.20M | 17.58M |
| Total Liabilities | 47.82M | 42.84M | 65.59M | 60.88M | 57.58M | 36.75M |
| Stockholders Equity | -14.78M | -12.72M | -43.18M | -41.01M | -38.96M | -13.72M |
Cash Flow | ||||||
| Free Cash Flow | -106.00K | 1.97M | -4.54M | -16.15M | -6.94M | -12.77M |
| Operating Cash Flow | 1.50M | 2.46M | -4.54M | -17.17M | -6.41M | -12.72M |
| Investing Cash Flow | -1.60M | -490.00K | 21.00K | 332.00K | -529.00K | -20.05M |
| Financing Cash Flow | 6.14M | 6.35M | 5.21M | 17.38M | 5.12M | 33.45M |
Sanuwave Health Technical Analysis
Sanuwave Health Risk Analysis
Sanuwave Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $335.94M | 24.21 | 7.64% | ― | 6.15% | -54.24% | |
| ― | $326.29M | 58.06 | 9.70% | ― | 27.22% | 695.07% | |
| ― | $250.56M | 19.06 | 10.79% | ― | 17.11% | 45.34% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $281.80M | ― | -35.98% | ― | 13.25% | 23.81% | |
| ― | $287.18M | ― | -102.61% | ― | 5.94% | 25.18% | |
| ― | $247.96M | ― | ― | ― | 57.43% | -155.29% |
Sanuwave Health Corporate Events
On September 25, 2025, Sanuwave Health terminated its former President, Andrew Walko, without cause, effective October 24, 2025. As part of the separation, Walko will receive a severance package including cash payments and continued vesting of stock options, with provisions for confidentiality and non-disparagement, impacting the company’s leadership structure.
The most recent analyst rating on (SNWV) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
On September 25, 2025, Sanuwave Health appointed Daniel Coyle as the new Chief Operating Officer, succeeding Peter Stegagno, who transitioned to Chief Regulatory Officer. Additionally, the company announced the termination of President Andrew Walko, effective October 24, 2025, with no immediate plans to appoint a successor.
The most recent analyst rating on (SNWV) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
On September 25, 2025, Sanuwave Health, Inc. entered into a credit agreement with JPMorgan Chase Bank for a $23 million term loan and a $5 million revolving credit facility. This refinancing allowed Sanuwave to repay its previous debt facility with NH Expansion Credit Fund Holdings LP, marking a significant step in strengthening its financial position by reducing interest rates and overall debt load, thereby enhancing cash flow generation.
The most recent analyst rating on (SNWV) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
Sanuwave, Inc. entered into an exclusive license and option agreement on March 6, 2024, with a third-party licensee concerning its patents in the intravascular shockwave applications field. The Licensee exercised its option to acquire the patents on August 21, 2025, resulting in a $5 million cash payment to Sanuwave, Inc., following an initial $2.5 million payment.
The most recent analyst rating on (SNWV) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
On August 19, 2025, Sanuwave Health held its annual meeting of stockholders where several key proposals were voted upon. The stockholders elected five directors, ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm, approved an amendment to the 2024 Equity Incentive Plan to increase shares, and voted on executive compensation matters. These decisions reflect the company’s ongoing governance and strategic planning efforts.
The most recent analyst rating on (SNWV) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Sanuwave Health stock, see the SNWV Stock Forecast page.
SANUWAVE Health Inc. recently held its Q2 2025 earnings call, revealing a generally positive outlook despite some financial challenges. The company reported significant revenue growth and strong sales of its UltraMIST systems, alongside robust gross margins. However, decreased net income and increased operating expenses, primarily due to non-recurring items and stock compensation, were noted as challenges. The expansion of the sales team and improvements in applicator production further contributed to the positive sentiment expressed during the call.
Sanuwave Health, Inc., a company specializing in FDA-approved wound care products, has reported its financial results for the second quarter of fiscal year 2025. The company, which focuses on non-invasive medical systems for tissue repair and regeneration, operates primarily in the healthcare sector.